TY - JOUR
T1 - Building a Robust Investigator-Initiated Platform
T2 - The I-CARE Experience
AU - Kirchgesner, Julien
AU - Beaugerie, Laurent
AU - Baumann, Cédric
AU - Baert, Filip
AU - Rahier, Jean-François
AU - Bergemalm, Daniel
AU - Cañete, Fiorella
AU - Caron, Bénédicte
AU - Cossignani, Marta
AU - Dias, Sandra
AU - Farkas, Klaudia
AU - Girod, Parker
AU - Goren, Idan
AU - Holvoet, Tom
AU - Krasz, Susanne
AU - Kumar, Aditi
AU - Rimmer, Peter
AU - Sheridan, Juliette
AU - Thut, Jessica
AU - Uzzan, Mathieu
AU - Viazis, Nikos
AU - Weimers, Petra
AU - Zagórowicz, Edyta
AU - Buisson, Anne
AU - Avedano, Luisa
AU - Rousseau, Helene
AU - Peyrin-Biroulet, Laurent
AU - Sebastian, Shaji
AU - I-CARE collaborator group
N1 - © 2026 The Author(s). Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
PY - 2026/2/15
Y1 - 2026/2/15
N2 - Investigator-initiated studies that include information collected by patients are rising, but limited data is available on patient and investigator experience in this setting. The I-CARE cohort included patients with inflammatory bowel disease (IBD) monthly collecting clinical information in 15 countries for up to 6 years. We describe patients and investigators' involvement in I-CARE and identify predictors of early withdrawal due to patient non-engagement. Patients' characteristics according to the number of electronic Patient-reported outcomes (ePRO) completed during follow-up were assessed. Predictors of early withdrawal due to patient non-engagement were identified using logistic regression. The coding of outcomes reported by patients and corrections by investigators on patients' ePROs were assessed. Among 12,846 patients included by 502 investigators, 79.3% and 77.3% filled more than one ePRO and at least one ePRO within 6 months before the study end date, respectively. All ePROs were completed in 72.8% and 56.4% of patients during year 1 and 3, respectively. Male gender, younger age (< 20), being unemployed or a student, and no previous history of abdominal surgery were associated with early withdrawal. Investigators corrected 52.5% of cancer or dysplasia reported by patients compared to 10% of serious infections. Investigators added or removed a treatment sequence in 19.6% of the 6708 patients treated with biologics. These results highlight the implication of patients in research and the importance of data validation by investigators alongside the challenge and potential of collecting medical data from patients. These findings can inform similar future initiatives in other diseases. (EudraCT, Number: 2014-004728-23; ClinicalTrials.gov, Number: NCT02377258).
AB - Investigator-initiated studies that include information collected by patients are rising, but limited data is available on patient and investigator experience in this setting. The I-CARE cohort included patients with inflammatory bowel disease (IBD) monthly collecting clinical information in 15 countries for up to 6 years. We describe patients and investigators' involvement in I-CARE and identify predictors of early withdrawal due to patient non-engagement. Patients' characteristics according to the number of electronic Patient-reported outcomes (ePRO) completed during follow-up were assessed. Predictors of early withdrawal due to patient non-engagement were identified using logistic regression. The coding of outcomes reported by patients and corrections by investigators on patients' ePROs were assessed. Among 12,846 patients included by 502 investigators, 79.3% and 77.3% filled more than one ePRO and at least one ePRO within 6 months before the study end date, respectively. All ePROs were completed in 72.8% and 56.4% of patients during year 1 and 3, respectively. Male gender, younger age (< 20), being unemployed or a student, and no previous history of abdominal surgery were associated with early withdrawal. Investigators corrected 52.5% of cancer or dysplasia reported by patients compared to 10% of serious infections. Investigators added or removed a treatment sequence in 19.6% of the 6708 patients treated with biologics. These results highlight the implication of patients in research and the importance of data validation by investigators alongside the challenge and potential of collecting medical data from patients. These findings can inform similar future initiatives in other diseases. (EudraCT, Number: 2014-004728-23; ClinicalTrials.gov, Number: NCT02377258).
U2 - 10.1002/cpt.70231
DO - 10.1002/cpt.70231
M3 - Journal article
C2 - 41693257
SN - 0009-9236
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
ER -